Pfizer Reports Phase 3 BASIS Trial Results for Marstacimab in Hemophilia

Pfizer today announced results from the Phase 3 BASIS trial evaluating marstacimab in patients with severe hemophilia A or B without inhibitors. The trial met its primary endpoint, demonstrating a significant reduction in treated annualized bleeding rate compared to prior prophylaxis. Marstacimab is a tissue factor pathway inhibitor (TFPI) antibody that restores hemostasis by blocking TFPI, a natural anticoagulant.